|
|
| |
|
| |
|
 |
|
| |
Redaktion: Maurie Markman
Atlas of Cancer
2. Auflage, 662 Seiten, 4 farbige Abbildungen, Gebunden
Springer-Verlag GmbH | ISBN: 1573402893
| |  | 203.25 EUR |  | | |
|
|
|
|
| |
Innerhalb 24 Stunden versandfertig. Expressversand: In Deutschland versandkostenfrei | Österreich: 4 € | Schweiz: ab 4 € | Europaweit ab 6 €. Versandkostenübersicht weltweit. Alle Preise inkl. MwSt. |
|
|
Ähnliche Bücher anzeigen
|
|
|
| |
| |
| VORWORT | öffnen |
|
PrefaceThe ongoing and truly spectacular revolution in our understanding of the molecular events associated with the development and progression of cancer has led to impressive advances in the management of malignant disease. From novel "targeted" therapies to innovative multi-modality treatment strategies (eg, chemoradiation; neoadjuvant chemotherapy followed by surgery) designed to optimize the effectiveness (and reduce the toxicity) of the individual approaches, and to a critically important ...
[weiter lesen]
|
|
|
| KLAPPENTEXT | öffnen |
|
The second edition of the Atlas of Cancer highlights the major features of current cancer management and clearly presents fundamental facts regarding our understanding of the etiology and pathophysiology of malignant disease. Guided by Dr. Maurie Markman, leading oncology experts combine remarkable illustrations, clinical photographs, instructive schematic diagrams, informative charts, and detailed captions to form one large Atlas that can assist physicians in the diagnosis, treatment, ... [weiter lesen] |
|
|
| INHALTSVERZEICHNIS | öffnen |
Contents I. Head and Neck Barbara A. Murphy Chapter 1 General Epidemiology, Staging, and Pathology 2 Barbara A. Murphy Chapter Surgical Management of Head and Neck Cancer 10 Brian B. Burkey Chapter 3 Radiation Therapy for Head and Neck Cancers 16 Anthony J. Cmelak Chapter 4 Overview of Treatment of Head and Neck Cancer 31 Jill Gilbert Chapter 5 Metastatic or Recurrent Head and Neck Cancer and-Issues in Symptom Control 39 Barbara A. Murphy and Jill Gilbert II. Gynecologic Cancers Richard R. Barakat and Douglas A. Levine Chapter 6 Genetics of Hereditary Gynecologic Cancers 46 Douglas A. Levine, Noah D. Kauft, and Jeff Boyd Chapter 7 Management of Early Epithelial Ovarian Cancer 54 Alan C. Schlaerth, Jakob Dupont, Martee L. Hensley, Mario M. Leitao, Jr, and Carol L.... Chapter 8 Management of Advanced Epithelial Ovarian Cancer 60 Yukio Sonoda and Paul Sabbatini Chapter 9 Management of Nonepithelial Ovarian Cancer 68 Susannah M. Mourton, Dennis S. Chi, and Martee L. Hensley Chapter 10 Management of Uterine Sarcomas 74 Bhavana Pothuri and Martee L. Hensley Chapter 11 Surgical Management of Endometrial Cancer 78 Destin R. Black and Nadeem R. Abu-Rustum Chapter 12 Nonsurgical Management of Endometrial Cancer 82 Jason A. Konner and Kaled M. Alektiar Chapter 13 Radical Surgery for Early and Recurrent Cervical Cancer 86 Eric L. Eisenhauer and Douglas A. Levine Chapter 14 Chemoradiation for Cervical Cancer 94 Kaled M. Alektiar and William P. Tew Chapter 15 Management of Vulvar Cancer 99 Sarah E. Ferguson and Mary L. Gemignani Chapter 16 Gestational Trophoblastic Disease 106 Margrit M. Juretzka and Carol Aghajanian III. Lung Cancer Roy S. Herbst Chapter 17 Lung Cancer Detection and Staging 118 John J. Mullon, James R. Jett, and Karen L. Swanson Chapter 18 Photodynamic Therapy for Early Stage Lung Cancer 130 Harvey I. Pass Chapter 19 Thoracoscopic Techniques in the Staging and Resection of Lung Cancer 137 Mathew Ninan Chapter 20 Surgical Management of Non -Small-cell Lung Cancer 144 Douglas R. Smego, Steven M. Keller, and John P. Nabagiez Chapter 21 Radiotherapy of Locally Advanced Non- Small-cell Lung Cancer 153 Robert M. MacRae and Hak Choy Chapter 22 Neoadjuvant Therapy for Locally Advanced Non- Small-cell Lung Cancer 163 Alex Metzger, Zelanna Goldberg, Peter F. Roberts, David M. Jablons, Derick Lau, David... Chapter 23 Surgical Management of Malignant-Pleural Mesothelioma 169 Harvey I. Pass and Michèle Carbone Chapter 24 Thymoma 175 Patrick J. Loehrer, Sr. and John D. Henley Chapter 25
[weiter lesen] |
|
|
|
|
| REGISTER | öffnen |
Index AAcquired melanocytic nevi, 509 Acromegaly, 613 Actinic keratosis, 504, 539-540 Acute lymphoblastic leukemia central nervous system, 309 - chemotherapy for, 312 - diagnosis of, 305 - histopathology of, 304 - mediastinal, 310 - minimal residual disease in, 311 - molecular and cytogenetic abnormalities in, 306-308 prognostic factors in, 308 - testicular, 311 Acute myelogenous leukemia chemotherapy for, 300-303 - histopathology of, 297-298 - molecular pathology of, 296-297 - prognosis of, 299 Acute promyelocytic leukemia, 297, 302 Adenocarcinoma esophageal, 215-218 Adenomas pituitary, 613-619 Adjuvant therapy for melanoma, 559 - for prostate cancer, 468-470 Adnexal cancer ovarian, 56 - skin, 576 AIDS central nervous system lymphoma in, 620 Allogeneic stem cell transplant in leukemia, 331-332 Altered fractionation radiation therapy, 23, 156 American Joint Committee on Cancer staging - of colorectal cancer, 244 - of kidney cancer, 483 - of melanoma, 557 - of vulvar cancer, 101 Amputation for sarcoma, 381, 394 Anaplastic large cell lymphoma, 362, 365 Androgen deprivation for prostate cancer, 468-470, 471-472 Angiogenesis inhibitors of, 189, 191, 413 - vascular endothelial growth factor pathway in, 282 Angiokeratoma, 555 Angiosarcoma, 414, 421, 577 Arsenical keratosis, 505 Asbestos mesothelioma and, 169 Astrocytoma, 600, 606-608, 651 BBarrett's esophagus, 207-210 Basal cell carcinoma complications of, 526 - diagnosis of, 519, 525 - epidemiology and risk of, 522-524 - genetics of, 524 - in Gorlin's syndrome, 654 - melanoma versus, 555 - precursors to, 503 - recurrent, 526-527, 530-531 - treatment of, 527-531 B-cell chronic lymphoid leukemia/small cell lymphocytic lymphoma, 359, 363 B-cell lymphoma, 360, 363, 368 Bevacizumab, 249, 255 Biliary cancer, 225-226 Biological therapy for endometrial cancer, 85 - for lung cancer, 160 Bladder cancer chemotherapy for, 479 - diagnosis and staging of, 476-477 - molecular markers in, 478 - overview of, 459 - prognosis in, 480 Bleomycin toxicity, 497 Bone marrow disorders. See specific disorders Bone sarcoma chemotherapy for, 401-407 - imaging of, 374-377 - recurrent, 386 - surgery for, 379-386 - team approach to, 407 Bowenoid papulosis, 506 Brachytherapy for lung cancer, 157 - overview of, 18 - in soft tissue sarcoma, 391 Brain abscess, 595 Brain death evaluation, 598 Brain tumors.See also specific tumors - central nervous system lymphoma as, 620-622 - diagnostic imaging of, 594-600 - diagnostic neuropathology of, 584-593 - epidemiology of, 582 - glial, 602-612 - meningioma as, 623-631 - molecular classification of, 593 - neurogenetic syndromes and, 646-654 - pathogenesis and genetics of, 583 - pituitary, 612-619 Breast cancer breast conservation in, 419 breast reconstruction in, 448-457 - classification of, 422 - clinical images of, 418-421 - genetics of, 48-49 - lymph node metastases in, 439 - lymphoscintigraphy in, 420 - magnetic resonance images of, 426-431 - mammographie images of, 441-443 - metastatic, 635 - multimodality images of, 445-447 - overview of, 417 - pathology of invasive, 422-425 - prevention of, 417 - radiation therapy for, 432-435 - response to chemotherapy in, 440 - staging of, 439 - ultrasound images of, 436-440 Breast Imaging Reporting and Data System, 441 Breast reconstruction postmastectomy, 448-457 Bronchioloalveolar carcinoma, 123-124 Burkitt lymphoma, 361, 364 Buschke-Lowenstein tumor, 533 CCA-125, 54-56 Capecitabine, 249-250 Carcinoid tumor, 600 Carcinosarcoma uterine, 75 Carmustine, 569 Cauda equina metastases, 637 Central nervous system. See also Brain tumors; - Neuro-oncology in acute lymphoblastic leukemia, 309 - lymphoma of, 620-622 Cerebrospinal fluid in brain tumor diagnosis, 584-585 - in leptomeningeal metastases, 635-637, 639 Cervical cancer, 86-97 chemoradiation for, 94-97 - epidemiology of, 86 - overview of, 45 - radiation therapy for, 94-97 - surgery for early-stage, 86-90 - surgery for recurrent, 90-93 Cetuximab, 249, 254, 282 Charing Cross scoring system for gestational trophoblastic disease, 112 Chemoimmunotherapy - for leukemia, 321 Chemoradiation for cervical cancer, 94-97 - for esophageal cancer, 219 - for gastric cancer, 203 - for head and neck cancer, 31, 36-37 - for rectal cancer, 269 - for vulvar cancer, 104 Chemotherapy for biliary cancer, 226 - for brain tumors, 604-605, 630 - for central nervous system lymphoma, 622 - for colorectal liver metastases, 260 - for cutaneous T-cell lymphoma, 568-569 - for endometrial cancer, 84 - for esophageal cancer, 219 - for gastric cancer, 203-206 - for gestational trophoblastic disease, 114-115 - for head and neck cancer, 32-35, 42-43 - for Hodgkin lymphoma, 352-354 - for leukemia, 300-303, 312, 318-319 - for lung cancer, 117, 151, 157-158, 163-168, 190 - for metastatic colorectal cancer, 248-253 - for mycosis fungoides, 570 - for ovarian cancer, 64-66, 69, 71-72 - for pancreatic cancer, 197-200 - for prostate cancer, 470, 474 - for rectal cancer, 268-269 - for sarcoma, 401-407, 410-414 - for testis cancer, 495-498 - for thymoma, 183-184 - for uterine sarcomas, 75-76 Child's Pugh liver cirrhosis score, 221-222 Chondrosarcoma, 376-377, 407, 414 Chordoma, 414 Choriocarcinoma, 110, 490 Chromogen-based in situ hybridization, 589 Chronic eosinophilic leukemia/ hypereosinophilic syndrome, 343-344 Chronic idiopathic myelofibrosis, 338-342 Chronic lymphocytic leukemia chemoimmunotherapy for, 321 chemotherapy for, 318-319 - diagnosis of, 315 - epidemiology of, 314 - genetics of, 316-317 - immunophenotyping of, 315 - monoclonal antibody therapy for, 320 - staging of, 316 Chronic myelogenous leukemia allogeneic stem cell transplant in, 331-332 - basal cell carcinoma in, 523 - epidemiology of, 323 - genetics of, 324 - histopathology of, 327 - imatinib therapy in, 329-332 - molecular biology of, 325-326 - prognostic factors in, 327-328 Chronic myelomonocytic leukemia, 291 Cirrhosis, 221-222 CLIP hepatocellular carcinoma scoring system, 222 Colonoscopy, 246, 264 Colorectal cancer adenoma-to-carcinoma sequence in, 239-240 chemoprevention of, 245 chemotherapy for metastatic, 248-255 - diagnosis of, 246 - endoscopic resection of, 247 - epidemiology of, 238 - genetic progression model in, 239-241 - liver metastases in, 258-262 - pathology of, 243 - predisposing conditions in, 241-242 - prognostic markers in, 280-281
[weiter lesen] |
|
|
|
|
|
|